Movement Alert｜Charles River Laboratories Intraday Rise 5.34%, UBS Upgrade and Probiotic Testing Agreement Drive Gains

Market Focus10-05 23:50

On October 5, Charles River Laboratories rose 5.34% in Regular Trading, trading near $306, with Turnover of $142 million. This move follows UBS's substantial target price increase to $357 from $175 and the company's new contract providing plasmid copy number testing for probiotic candidates targeting muscle health in GLP-1 weight loss therapies.

UBS analysts upgraded Charles River to Buy from Neutral, setting the highest price target among major banks and citing strong margin potential in Discovery and Safety Assessment services. Simultaneously, the new NorthStrive Biosciences agreement positions Charles River at the intersection of the $100B GLP-1 market and next-generation microbiome therapies, expanding its manufacturing quality control offerings. These developments build on recent analyst optimism from RBC and Argus, both projecting significant upside.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment